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Numerous peptides isolated from rat heart atria, including two containing 33 and 73 amino acids, were 
isolated and shown to exhibit natriuretic activities. Here, we describe the purification and partial amino 
acid sequence of a 106-residue peptide containing the previously sequenced 33- and 73-amino-acid ANF 
peptides. The determined sequence is a novel one and is not significantly homologous to any known 
protein or segment hereof. In fact, this sequence shows significant homology only to another novel partial 
sequence obtained from sequence analysis of a porcine peptide, called cardiodilatin, also found in heart 
atria. This relationship is taken as evidence that ANF and cardiodilatin are part of the same precursor 
molecule which would contain at the very least 126 amino acids. 
Pronatriodifatin Cardiodilatin 
1. INTRODUCTION 
The presence in mammalian heart atria 
homogenates of numerous potent peptides possess- 
ing natriuretic and smooth muscle relaxant ac- 
tivities is now firmly established. Indeed, gel filtra- 
tion separations have indicated that biological ac- 
tivities could be recovered in both high- and low- 
44; material [l-S]. Chemical characterization in- 
cluding amino acid sequence determination has 
been successfully accomplished by many 
laboratories on the low-M, peptides exhibiting 
natriuretic properties. Indeed, the atrial natriuretic 
factor (ANF) was shown by amino acid sequencing 
and by chemical synthesis to correspond to a pep- 
tide containing one disulfide bridge and compris- 
ing between 21 and 33 amino acids [6-g]. 
Moreover, all structures shown share the same 
common amino acid sequence xcept in the case of 
the human ANF (in preparation) [9] which con- 
tains a methionine residue instead of the isoleucine 
Amino acid sequence Precursor 
found in the rat ANF [6-81. Also, in all cases, the 
isolated native peptide and its synthetic replica ex- 
hibited comparable biological activities. All these 
forms represent an amino-terminal truncated ver- 
sion of the 33-amino-acid peptide [6,10], except in 
the case of the peptides reported in (81 which are 
also truncated at the carboxy-terminal, 
However, size heterogeneity of the biologically 
active molecule was observed in most studies and, 
in some of them, the presence of larger molecules 
of active material was reported [l-5]. Recently, 
the amino acid sequence of a 73-residue peptide, 
together with evidence of an even larger one, both 
containing at their C-termini the previously se- 
quenced 33-amino-acid ANF peptide, were 
reported [3]. Moreover, demonstration of a heat- 
labile factor responsible for the conversion of 
high-Mr to low-M, natriuretic activity was ac- 
complished in rat atria [1 I] thus adding weight to 
the proposa1 that the low-M, ANF is contained in 
a much larger protein or precursor. 
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Interestingly, authors in [ 121 reported recently 
the presence in pig heart atria of a new low-M, pep- 
tide which exhibits vasodilator effects but does not 
stimulate diuresis. Indeed this peptide, tentatively 
named ‘cardiodilatin’, has an M, value of about 
7500 and exhibits a strong smooth muscle relaxant 
activity when tested upon the aorta or renal artery. 
Here again, as in the case of ANF, numerous pep- 
tides present in the extract are able to exhibit a 
relaxing activity upon vascular smooth muscle. 
Here we present the purification and partial se- 
quence analysis of the second high-M, form iden- 
tified (ANF-H2) in [3]. Furthermore, we show that 
it is composed of 106 amino acids in which the first 
33 residues precede the 73 amino acids in ANF-Hl . 
Moreover, we discuss the relationship of the 
presented sequence of ANF-H2 with the first 
30-amino-acid sequence reported for cardiodilatin 
and propose that ANF and cardiodilatin [12] are 
part of the same precursor molecule. Both of these 
moieties, seemingly exhibiting two different 
biological activities, are thus contained in a protein 
or precursor having at the very least 126 amino 
acids. 
2. MATERIALS AND METHODS 
2.1. Biological assay 
The natriuretic activity of the purified peptide 
was determined in 200 g anesthetized female 
Sprague-Dawley rats as in [2,13]. Results were 
calculated as req. Na+ excreted/20 min. 
A chick rectum assay [5] was used to determine 
the vasorelaxant activity. Results were expressed in 
comparison with synthetic ANF. 
2.2. Purification of the ANF-H2 form 
Purification of the ANF-H2 form from 48 g 
atria (650 rats) was accomplished as in [3]. Final 
purification was achieved on a C18 r-Bondapak 
column eluted with 0.13% (v/v) heptafluorobu- 
tyric acid and acetonitrile. 
2.3. Amino acid and sequence analysis 
Amino acid analyses of the reduced and carbox- 
ymethylated ANF-H2 were done in duplicate 
following hydrolysis in 5.7 N HCl in vacua at 
108°C for 24 h. Separation and quantitation of the 
amino acids were done as in [3]. 
Automatic amino-terminal Edman degradation 
on the reduced and alkylated ANF-H2 was per- 
formed using a 0.33 M Quadrol program on a 
Beckman 890C sequenator equipped with a Se- 
quemat P6 autoconvertor and a model SC-510 
controller. Prior to sequencing, two precycles were 
run to clean the Polybrene (3 mg, Aldrich). 
Modifications to the running order of cycles in- 
cluded a double coupling procedure on cycle 1 to 
increase the initial yield and a double cleavage pro- 
cedure following two previously localized proline 
residues at cycles 4 and 12. Furthermore, in an ef- 
fort to decrease the background amount of 
phenylthiohydantoin (PTH) amino acid deriva- 
tives and to eliminate minor contaminating protein 
sequences, blockage of all the primary amino 
groups was accomplished prior to cycle 4. As sug- 
gested originally in [ 141, this can be done at a cycle 
corresponding to a proline residue by using a 
reagent, such as fluorescamine, reacting irrevers- 
ibly with free primary amino groups. In our case, 
it was accomplished by using a solution containing 
0.25% (w/v) o-phthalaldehyde (OPA; Fluoropa, 
Pierce) in methanol (HPLC grade, Burdick and 
Jackson); this reagent is used during the blocking 
cycle instead of the normal coupling reagent. After 
addition of the OPA solution, normal program- 
ming is resumed to the end, including the cleavage 
and extraction step, followed by a normal sequenc- 
ing cycle to remove the unmodified proline 
residue. PTH-amino acid derivatives were iden- 
tified and quantitated using PTH-norleucine as in- 
ternal standard by HPLC [15] on a Varian 5500 li- 
quid chromatograph equipped with a Vista 402 
plotter/integrator and with a WISP (Waters) 
automatic injector. 
3. RESULTS AND DISCUSSION 
As mentioned, molecular sieving on Bio-Gel P 10 
of the crude extract of rat atria resulted in the sub- 
division of the various active molecular entities. 
From the low-M, pool it was possible to purify and 
analyze, including amino acid sequencing, at least 
4 amino-terminal truncated forms of the longest 
33-residue ANF peptide [6,10]. All these 
homologous forms were shown to be biologically 
active and comparable in potency to a synthetic 
replica containing the last 26 amino acids [6]. 
From the high-M, pool, numerous elongated forms 
of ANF were identified but the amounts recovered 
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in most cases did not permit further characteriza- 
tions. Thus only two peptides, denoted ANF-Hl 
and ANF-HZ, recovered in yields between 50 and 
100 pg, could be further analyzed. ANF-HI was 
recently shown to be a 73-residue peptide contain- 
ing at its C-terminus the 33-amino-acid ANF while 
ANF-H2 was also reported to be an amino- 
terminal extended form [3]. Furthermore, a sub- 
fragment of rat ANF-Hl has been isolated and 
characterized [16]; the amino acid sequence 
presented is absolutely identical with the last 48 
residues of ANF-Hl. Fig.1 illustrates the elution 
profile of ANF-HZ, purified on a Cr8 p-Bondapak 
column eluted with the tri~uoroacetic acid-aceto- 
nitrile system: material corresponding to the bar 
under the peak was pooled together and repurified 
using the heptafluorobutyric acid-acetonitrile 
system where it elutes around 40% acetonitrile. 
The amino acid composition of purified ANF- 
H2 did not reveal any marked difference with the 
preliminary reported composition [3], except that 
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Fig. 1. Chromatography of peptide ANF-H2 on a Cl8 ,W 
Bondapak column eluted with acetonitrile (30-40%) in 
0.1% trifluoroacetic acid at a slope of 0.2%/min and a 
flow rate of 1 ml/min. 
one more Thr was found together with a higher 
number of Ser (11 instead of 9) and Gly (12 instead 
of 10). All other features, namely the high number 
of Ser, Gly, Glu, Pro, Leu and Arg combined with 
the same proportion of Ile, Tyr and Phe as com- 
pared to ANF l-33, were found to be unchanged. 
The natriuretic and relaxant activities as deter- 
mined by the natriuretic assay 12,131 and the chick 
rectum assay [5] of both high-iWr forms of ANF, 
ANF-Hl and ANF-H2 are compared in table 1 to 
the synthetic ANF comprising the last 26 residues 
located at the C-terminus. In both cases, the 
observed biological activities of ANF-Hl and 
ANF-H2 are 5- and IO-times lower, respectively, 
than for the synthetic ANF. 
Preliminary amino acid sequence data obtained 
while analyzing the products isolated during 
HPLC purification revealed the presence of at 
least 3 chains, namely a major one corresponding 
to Glu-Lys-Met-Pro.. . (50.1% based on recovery 
at cycle 1) and two others corresponding to His- 
Leu-Gtu-Glue.. and Lys-Met-Pro.. . (21.1 and 
28.8%, respectively). Upon further purification we 
were able to remove the His-Leu-Glu-Glu so that 
the amino acid sequencing was carried out on the 
major chain, the contribution of the other con- 
taminating sequence, Lys-Met-Pro.. . (represen- 
ting the N-l sequence), being eliminated by treat- 
ment with OPA at cycle 4. 
Fig.2 shows the identi~cation and yield of the 
various PTH-amino acids obtained during sequen- 
Table 1 
Biological activity of high-Mr forms of ANF compared 
to synthetic ANF (8-33) 
Chick rectum Natriuretic 
assaya assayb 
Synthetic ANF 100 270 f 47.1 
ANF-H 1 41.7 k 21.9 32.3 f 21.6 
(n = 4) (n = 4) 
ANF-HZ 17.8 + 8.3 16.6 f 13.3 
(n = 5) (n = 3) 
a The relaxant activity was compared to an equimoiar 
dose of synthetic ANF 
b The natriuretic activity was measured in change ofpeq. 
Na+ excreted in 20 min for a dose of 500 pmol for each 
peptide 
Values are expressed as 070 
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1. 3 
~ 
CYCLE NUMBER 
Fig.2. Automatic NHz-terminal degradation of the ANF-H2 peptide. Quantitative yields of PTH-amino acids 
normalized to a PT~-norieucine internal standard are illustrated as a function of residue numbers. The slope and 
intercept were obtained by a linear regression analysis on selected stabie PTH-amino acids giving the repetitive yield 
and initial yield, respectively. 
cing of ANF-H2. The repetitive and initial yield 
were computed from the linear regression line to be 
93.17% and 742 pmol, respectively, with a correla- 
tion coefficient of 0.866. As can be seen in fig.2, 
amino acids occupying positions 27, 28 and 30 
could not be quantitated nor could they be iden- 
tified positively. This can probably be best ex- 
plained by the presence in those cycles of labile 
amino acids that are destroyed during conversion 
(like Ser and Thr), since even at this low level 
(100 pmol) the amino acid sequence was clearly 
seen up to cycle 35. Moreover, addition of OPA at 
cycle 4, as described in section 2.3, was certainly 
not deleterious to the repetitive yield and, in con- 
trast, it helped to remove the contribution of the 
Lys-Met-Pro.. , sequence representing 25oib of the 
sequenceable material and of another unidentified 
sequence present in very low amounts. After 
treating the sequenced chain at the Pro residue 
with OPA solution, we experienced some loss of 
amino-terminal function as evidenced by the 
recovery of 1 nmol Met at cycle 3 as compared to 
600 pmol Pro at cycle 4 even though this could also 
be due to the known resistance of bonds involving 
Pro residues during the cleavage reaction. Never- 
theless, from that cycle onwards, only one se- 
quence was observed with minimal background 
thus allowing the sequence to continue up to 35 
cycles. Clearly, as shown in fig.3, based upon the 
presented ata of the sequence of ANF-H2 and the 
presence of the His-Leu-Glu-Glu sequence, the 
identity proposed solely from the amino acid com- 
position of ANF-H2 is established as being an 
amino-terminal extended form of ANF-Hl and of 
ANF l-33. Indeed, one can find a 5-amino-acid 
stretch, namely Glu-Val-Pro-Pro-Trp, at the end 
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Fig.3. Complete amino acid sequence of the IOdresidue 
ANF peptide also comprising the sequence of ANF-HI 
and of the 33-residue ANF starting at positions 34 and 
74, respectively. 
of the sequence of ANF-H2 which overlaps the se- 
quence starting at position 34 of ANF-HI. Thus, 
it can be concluded, based upon those sequence 
data and on amino acid composition, that the Iow- 
M, ANF peptide is located at the C-terminal por- 
tion of ANF-Hl which itself is contained in the 
larger ANF-H2. 
As found in the case of ANF-Hl a computer 
data bank search was performed using the Na- 
tional Biomedical Foundation Mutation data 
matrix program and Sequence data bank 
(Georgetown University, Washington, DC). When 
compared to the 2700 protein sequences in the data 
bank, no significant homology (> 30%) was found 
confirming the novel character of that sequence. 
On the other hand, authors in [12] recently 
reported preliminary data including a partial 
amino acid sequence concerning a new peptide, 
cardiodilatin, able to exert a relaxing activity upon 
vascular smooth muscle. This amino acid se- 
quence, corresponding to the first 30 amino acids 
of cardiodilatin, was also shown to be novel since 
no significant homology could be found using the 
same procedure as for ANF-H2. Interestingly, 
when one compares these two novel sequences, a
strongly homologous region, as indicated in fig.4, 
can be identified between the last 10 residues of 
cardiodilatin and the first 10 of the 106-residue 
ANF-H2. Indeed, in that sequence 8 amino acids, 
namely His, Leu, Glu, Lys, Met, Pro, Glu and 
Asp, are identical in both sequences while the two 
84 
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Fig.4. Amino acid sequence homology between 
cardiodilatin [12] and the first 13 residues of the 
lodresidue ANF. Identical amino acids are enclosed in 
boxes for comparison. 
others could result from a single base change in the 
codon. Moreover, those two substitutions are of a 
conservative nature since Asp and Leu are replaced 
by Glu and Val, respectively; they could result 
from species differences because cardiodilatin was 
isolated from porcine atria1 tissue while ANF-H2 
was isolated from rat atrial tissue. Considering the 
novel character of both sequences and the almost 
perfect match of 10 amino acids as far as physico- 
chemical characteristics are concerned (80% 
homology in true identity), it can thus be conclud- 
ed that both molecules, cardiodilatin and ANF, are 
part of the same precursor molecule. The ANF 
moiety is located at the C-terminus while car- 
diodilatin is much closer to the as yet unidentified 
N-terminus. Moreover, the complete cDNA se- 
quence coding for both cardiodilatin and ANF 
confirms entirely those results and, furthermore, 
shows that only 6 amino acid differences exist bet- 
ween the sequence of rat and the first 30 amino 
acids of porcine cardiodilatin (in preparation). 
Thus, this molecule of at least 126 residues could 
be responsible for the distribution of both 
biological activities, the natriuresis and vascular 
smooth muscle relaxation, in high-Mr fractions 
when atria1 extracts are analyzed by molecular 
sieving. It can also be surmised, based upon the 
relationship between the two activities, that a way 
must exist in which both activities, present in the 
same molecule, are separated. Indeed, authors in 
[12j reported that highly purified cardiodilatin, 
when tested upon renal function, results in loss of 
diuretic activity while crude fractions are able to 
stimulate it; this could thus be explained by the 
presence of the ANF moiety in the crude 
preparation. 
Volume 172, number 1 FEBS LETTERS June 1984 
Conceivably, that molecule of 126 amino acids 
must be processed so as to release both activities; 
this could be accomplished by the heat-labile fac- 
tor identified in [ 111. Based upon the presented se- 
quence, that molecule, which might be called ‘pro- 
natriodilatin’, is almost devoid of pairs of basic 
amino acids which are known to be recognized and 
cleaved during maturation of prohormone precur- 
sors [ 171. The only pair, Arg-Arg, present is 
located at position 81-82 in the 106~residue s - 
quence and seems to be slightly cleaved since small 
amounts of fragment 83-106 have been isolated 
[6-lo]. 
Furthermore, the different ANF molecules 
could possibly arise by non-specific chemical or 
proteolytic degradation during the extraction pro- 
cedure as exemplified by the 48”amino-acid frag- 
ment characterized in [ 161 which could result from 
cleavage at an acid-labile Asp-Pro bond. Alter- 
natively, they could be obtained from cleavage 
arising at various Leu residues located at positions 
2, 32, 73, 74 and 80 yielding ANFC106, 
ANF34-106, ANF74-106, ANF75-106 and 
ANF8f-106, respectively. In some cases, further 
degradation by an aminopeptidase, made plausible 
by the presence of an N-l sequence found during 
sequencing of ANF-HZ, would produce the 
observed fragments. Interestingly, the fragmenta- 
tion pattern seems to follow the distribution of Leu 
pairs of which two can be located at position 
18-19 of cardiodilatin thus preceding the 103- and 
106-residue fragments and at position 73-74 of 
ANF I-106 preceding the smaller (< 33 residues) 
ANF peptides. The presence of consecutive Leu 
residues that could act as recognition sites for pro- 
cessing was also observed by authors in [18]; they 
isolated 4 different naturally occurring fragments 
arising from cleavages at the carboxyl side of con- 
secutive Leu residues in the glycopeptide represen- 
ting the C-terminal of propressophysin [ 191. Other 
Leu cleavages are known to occur during matura- 
tion of prorelaxin to relaxin at the junction of the 
B and C chain [20], in the production of LPH 
61-76 [21] and in the renin-angiotensin system 
[22]. Finally, it is worth noting that production of 
kallidin (Lys-bradykinin) by glandular kallikrein is 
accomplished through cleavage on kininogen of a 
neutral amino acid, Met, following a Leu residue 
[23]; this cleavage is quite similar to that observed 
in pronatriodilatin where bonds located one 
residue away from Leu are cleaved. On the other 
hand, the ANF peptides starting at position 79 
described in [7] and 191 could result from cleavage 
at a single Arg residue; however, this cleavage can- 
not explain the occurrence of the 73-, 103- and 
106-residue forms. Nevertheless, cleavages at a 
single Arg were observed in the case of prohor- 
mones, notably during conversion of chicken pro- 
albumin [24], propressophysin [19], pro- 
cholecystokinin 1251, prosomatocrinin [26] and 
prosomatostatin [27]. 
Finally, it can be concluded that cardiodilatin 
and ANF are part of the same precursor molecule, 
pronatriodilatin, which contains a minimum of 
126 residues as derived from protein sequencing. 
However, the heterogeneity of the various peptides 
responsible for natriuresis and smooth muscle 
relaxant activity still remains to be resolved. Fur- 
thermore, the maturation pathway, if any, for that 
precursor is at present unclear. Indeed, in view of 
its similarity to prohormone and proneuropeptide 
processing relying on single or paired basic 
residues, and to the angiotensin or bradykinin 
system relying more on the substrate specificity of 
the relevant enzymes, the maturation pathway can 
now be related to both. Knowing the 126-residue 
sequence and the nucleotide sequence should help 
greatly in following the steps during post- 
translational processing by allowing the use of 
region-specific antibodies and microsequencing, 
thus leading to a better knowledge of the biological 
activities of both ANF and cardiodilatin. Finally, 
it is interesting that a molecule like atria1 pro- 
natriodilatin might contain at least two bioactive 
fragments having complementary hypotensive 
effects. 
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